Lupin’s US subsidiary, Lupin Pharmaceuticals Inc. has received tentative approval from the United States Food and Drug Administration (USFDA) to market a generic equivalent of ViiV Healthcare’s (ViiV) Lexiva Tablets, 700 mg (Fosamprenavir Calcium Tablets, 700 mg). This product was filed from Lupin’s Goa formulations manufacturing facility.
Lupin’s Fosamprenavir Calcium Tablets, 700 mg are the AB rated generic equivalent of ViiV Healthcare’s Lexiva Tablets. It is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Lexiva Tablets had US sales of $71.6 million, as per IMS MAT March 2016 data.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.20 |
| Dr. Reddys Lab | 1293.20 |
| Cipla | 1314.50 |
| Zydus Lifesciences | 944.10 |
| Lupin | 2265.15 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: